SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-004091 to JUPITER NEUROSCIENCES, INC. (JUNS)

JUPITER NEUROSCIENCES, INC.
Date: April 22, 2026 · CIK: 0001679628 · Accession: 0000000000-26-004091

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295085

Date
April 22, 2026
Author
Division of
Form
UPLOAD
Company
JUPITER NEUROSCIENCES, INC.

Letter

Re: Jupiter Neurosciences, Inc. Registration Statement on Form S-3 Filed April 16, 2026 File No. 333-295085 Dear Christer Ros n:

April 22, 2026

Christer Ros n Chief Executive Officer Jupiter Neurosciences, Inc. 1001 North US HWY 1, Suite 504 Jupiter, FL 33477

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jeffrey Schultz, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 22, 2026

Christer Ros n
Chief Executive Officer
Jupiter Neurosciences, Inc.
1001 North US HWY 1, Suite 504
Jupiter, FL 33477

 Re: Jupiter Neurosciences, Inc.
 Registration Statement on Form S-3
 Filed April 16, 2026
 File No. 333-295085
Dear Christer Ros n:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jeffrey Schultz, Esq.
</TEXT>
</DOCUMENT>